161 related articles for article (PubMed ID: 19615749)
1. Application of specific cell permeable cathepsin G inhibitors resulted in reduced antigen processing in primary dendritic cells.
Reich M; Lesner A; Legowska A; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
Mol Immunol; 2009 Sep; 46(15):2994-9. PubMed ID: 19615749
[TBL] [Abstract][Full Text] [Related]
2. Specific cathepsin B inhibitor is cell-permeable and activates presentation of TTC in primary human dendritic cells.
Reich M; Wieczerzak E; Jankowska E; Palesch D; Boehm BO; Burster T
Immunol Lett; 2009 Apr; 123(2):155-9. PubMed ID: 19428564
[TBL] [Abstract][Full Text] [Related]
3. Invariant chain processing is independent of cathepsin variation between primary human B cells/dendritic cells and B-lymphoblastoid cells.
Reich M; Zou F; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
Cell Immunol; 2011; 269(2):96-103. PubMed ID: 21543057
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin G is differentially expressed in primary human antigen-presenting cells.
Stoeckle C; Sommandas V; Adamopoulou E; Belisle K; Schiekofer S; Melms A; Weber E; Driessen C; Boehm BO; Tolosa E; Burster T
Cell Immunol; 2009; 255(1-2):41-5. PubMed ID: 19036358
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin E regulates the presentation of tetanus toxin C-fragment in PMA activated primary human B cells.
Burster T; Reich M; Zaidi N; Voelter W; Boehm BO; Kalbacher H
Biochem Biophys Res Commun; 2008 Dec; 377(4):1299-303. PubMed ID: 18996084
[TBL] [Abstract][Full Text] [Related]
6. Modulation of antigen processing and presentation by covalently linked complement C3b fragment.
Jacquier-Sarlin MR; Gabert FM; Villiers MB; Colomb MG
Immunology; 1995 Jan; 84(1):164-70. PubMed ID: 7890301
[TBL] [Abstract][Full Text] [Related]
7. Masking of a cathepsin G cleavage site in vivo contributes to the proteolytic resistance of major histocompatibility complex class II molecules.
Burster T; Macmillan H; Hou T; Schilling J; Truong P; Boehm BO; Zou F; Lau K; Strohman M; Schaffert S; Busch R; Mellins ED
Immunology; 2010 Jul; 130(3):436-46. PubMed ID: 20331476
[TBL] [Abstract][Full Text] [Related]
8. Interferon-gamma regulates cathepsin G activity in microglia-derived lysosomes and controls the proteolytic processing of myelin basic protein in vitro.
Burster T; Beck A; Poeschel S; Øren A; Baechle D; Reich M; Roetzschke O; Falk K; Boehm BO; Youssef S; Kalbacher H; Overkleeft H; Tolosa E; Driessen C
Immunology; 2007 May; 121(1):82-93. PubMed ID: 17302735
[TBL] [Abstract][Full Text] [Related]
9. Application of a novel highly sensitive activity-based probe for detection of cathepsin G.
Zou F; Schmon M; Sienczyk M; Grzywa R; Palesch D; Boehm BO; Sun ZL; Watts C; Schirmbeck R; Burster T
Anal Biochem; 2012 Feb; 421(2):667-72. PubMed ID: 22178917
[TBL] [Abstract][Full Text] [Related]
10. Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincense.
Tausch L; Henkel A; Siemoneit U; Poeckel D; Kather N; Franke L; Hofmann B; Schneider G; Angioni C; Geisslinger G; Skarke C; Holtmeier W; Beckhaus T; Karas M; Jauch J; Werz O
J Immunol; 2009 Sep; 183(5):3433-42. PubMed ID: 19648270
[TBL] [Abstract][Full Text] [Related]
11. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors.
Katunuma N; Matsunaga Y; Himeno K; Hayashi Y
Biol Chem; 2003 Jun; 384(6):883-90. PubMed ID: 12887055
[TBL] [Abstract][Full Text] [Related]
12. An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity.
Desai SN; White DM; O'shea KM; Brown ML; Cywin CL; Spero DM; Panzenbeck MJ
Eur J Pharmacol; 2006 May; 538(1-3):168-74. PubMed ID: 16631730
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases.
Ghittoni R; Napolitani G; Benati D; Ulivieri C; Patrussi L; Laghi Pasini F; Lanzavecchia A; Baldari CT
Eur J Immunol; 2006 Nov; 36(11):2885-93. PubMed ID: 17048274
[TBL] [Abstract][Full Text] [Related]
14. Identification of a potent and selective noncovalent cathepsin S inhibitor.
Thurmond RL; Sun S; Sehon CA; Baker SM; Cai H; Gu Y; Jiang W; Riley JP; Williams KN; Edwards JP; Karlsson L
J Pharmacol Exp Ther; 2004 Jan; 308(1):268-76. PubMed ID: 14566006
[TBL] [Abstract][Full Text] [Related]
15. Natural processing sites for human cathepsin E and cathepsin D in tetanus toxin: implications for T cell epitope generation.
Hewitt EW; Treumann A; Morrice N; Tatnell PJ; Kay J; Watts C
J Immunol; 1997 Nov; 159(10):4693-9. PubMed ID: 9366392
[TBL] [Abstract][Full Text] [Related]
16. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation.
Manoury B; Hewitt EW; Morrice N; Dando PM; Barrett AJ; Watts C
Nature; 1998 Dec; 396(6712):695-9. PubMed ID: 9872320
[TBL] [Abstract][Full Text] [Related]
17. A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin A.
Zaidi N; Burster T; Sommandas V; Herrmann T; Boehm BO; Driessen C; Voelter W; Kalbacher H
Biochem Biophys Res Commun; 2007 Dec; 364(2):243-9. PubMed ID: 17937927
[TBL] [Abstract][Full Text] [Related]
18. Bm-CPI-2, a cystatin homolog secreted by the filarial parasite Brugia malayi, inhibits class II MHC-restricted antigen processing.
Manoury B; Gregory WF; Maizels RM; Watts C
Curr Biol; 2001 Mar; 11(6):447-51. PubMed ID: 11301256
[TBL] [Abstract][Full Text] [Related]
19. Bacterial surface display library screening by target enzyme labeling: Identification of new human cathepsin G inhibitors.
Jose J; Betscheider D; Zangen D
Anal Biochem; 2005 Nov; 346(2):258-67. PubMed ID: 16225837
[TBL] [Abstract][Full Text] [Related]
20. Novel cell-permeable acyloxymethylketone inhibitors of asparaginyl endopeptidase.
Loak K; Li DN; Manoury B; Billson J; Morton F; Hewitt E; Watts C
Biol Chem; 2003 Aug; 384(8):1239-46. PubMed ID: 12974392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
